Key facts
- This page summarizes Paul R. Edick's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2024, 17:04.
Paul R. Edick - 31 Jan 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)
- Reporting relationship
- Chairman and Chief Executive Officer, Director
- Issuer ticker
- XERS
- Reported as of
- 31 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2024, 17:04:32 UTC
- Prior SEC filing
- 09 Aug 2023
- Next SEC filing
- 04 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Beth Hecht, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul R. Edick filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 31 Jan 2024.
Change
- Previous filing in this sequence was filed on 09 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XERS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,500,000
- Change %
- +66%
- Price
- $0.000000
- Shares after
- 3,788,064
- Date
- 31 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
XERS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,430
- Date
- 31 Jan 2024
- Ownership
- By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XERS
transaction
Derivative
Stock Appreciation Right
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 31 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $2.46
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
Footnote F2
The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F3
The award will vest in full on the two-year anniversary of the grant date.
Footnote F4
Upon exercise, the Stock Appreciation Right will be settled in cash.
SEC remarks
Chairman and Chief Executive Officer